Table 4.
Associations between SNGH17 and clinicopathological characteristics of 52 PC patients.
| Characteristics | N | SNHG17 expression | p | |
|---|---|---|---|---|
| Low | High | |||
| Total cases | 52 | 26 | 26 | |
| Age (year) | ||||
| ≤70 | 32 | 10 | 22 | Not significant |
| >70 | 20 | 7 | 13 | |
| Gleason score | ||||
| ≤7 | 35 | 19 | 16 | 0.2453 |
| >7 | 17 | 6 | 11 | |
| Serum PSA (ng/μl) | ||||
| ≤20 | 19 | 6 | 13 | 0.4389 |
| >20 | 33 | 14 | 19 | |
| Tumor stage | ||||
| I-IIa | 33 | 18 | 15 | 0.0484∗ |
| IIb/IIc | 19 | 5 | 14 | |
| Bone metastasis | ||||
| Yes | 29 | 13 | 16 | 0.0744 |
| No | 23 | 16 | 7 | |
| Biochemical recurrence | ||||
| Yes | 19 | 4 | 15 | 0.0031∗∗ |
| No | 33 | 21 | 12 | |
| Overall survival | ||||
| Alive | 44 | 26 | 18 | 0.258 |
| Death | 8 | 3 | 5 | |